Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
US approval could mark the company's graduation to oncology.
The FDA will rule on a low dose of zongertinib in the summer.
Meanwhile, Tango tries again in PRMT5.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Halda, Accent and Vividion take more projects into phase 1.
